[ad_1]
|
||
| ▲ Celltrion CI./Photo = Celltrion | ||
Celltrion Group established Celltrion Healthcare Holdings on this day by investing in-kind shares of Celltrion Healthcare held by Chairman Seo Jeong-jin, Celltrion Healthcare’s largest shareholder, for the merger.
It is about separating ownership from management and strengthening governance. The company plans to establish a Celltrion Group holding company system by the end of next year promoting the merger between Celltrion Holdings and Healthcare Holdings immediately after the qualified merger requirements are met.
Along with this, it plans to quickly promote the merger of the three companies Celltrion, Celltrion Healthcare and Celltrion Pharmaceuticals when the requirements to restrict the actions of portfolio companies are met in the ‘Monopoly Regulation and Fair Trade Act’.
Celltrion Group may establish a portfolio company system by establishing Healthcare Holdings, thus ensuring a professional management system by separating ownership and management. Furthermore, since the merger of the three companies enables development, production, distribution and sales at the same time in a single company, it is expected to reduce costs and improve business transparency through a better transaction structure.
Celltrion Group expects the company’s business capabilities to expand significantly to compete with global Big Pharma. In the global biopharmaceutical market, it is necessary to become a pharmaceutical company with a scale to compete with the large global pharmaceutical companies that have put capital and scale ahead.
If the three companies merge, it will create a large-scale pharmaceutical company with a drug R&D, marketing and direct sales distribution network, and is expected to have greater influence and competitiveness in the global market.
When a competitive portfolio of important products such as biopharmaceuticals and chemicals is formed within the group and presented to the national and international markets, it is expected to contribute to the quantitative and qualitative growth of efficiency in terms of sales volume and unified sales channels.
A Celltrion Group official said: “This proposed merger is an effective way to enhance the Celltrion Group’s competitiveness and improve the transparency of business operations as a result of reviewing various proposals and thoroughly reviewing the content.” As approved by the shareholders, the agenda will be presented to the general shareholders ‘meeting by resolution of the board of directors of each company, and the objective, method and schedule will be determined in accordance with the results of the general shareholders’ meeting. ”
He then emphasized: “Through this reorganization of corporate governance, we will grow to become a comprehensive biotechnology company that leads the global pharmaceutical biotechnology market and carry out the company’s mission to promote human health and expand the medical well-being of people. patients.
[미디어펜=김견희 기자] ▶ See other articles
[ad_2]
